New data from LEQEMBI® (lecanemab-irmb) phase 3 Clarity AD study and subcutaneous formulation to be presented at CTAD

STOCKHOLM, Oct. 16, 2023 /PRNewswire/ — BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai will present new data from the phase 3 Clarity AD study for its Alzheimer’s disease (AD) treatment LEQEMBI® (lecanemab-irmb) 100 mg/mL injection for intravenous use, as well as new data…